Disease burden of herpes zoster in Sweden - predominance in the elderly and in women - a register based study

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Studahl, Marie ^a   Petzold, Max ^a   Cassel, Tobias ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Sanofi Pasteur MSD   (Sweden)

Author keywords

Antiviral prescriptions; Disease burden; Herpes zoster; Hospitalization; Mortality

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; FEMALE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; INFECTION COMPLICATION; MALE; MIDDLE AGED; MORTALITY; PERIPHERAL NEUROPATHY; PRESCRIPTION; REGISTER; SEX DIFFERENCE; SWEDEN; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HERPES ZOSTER; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; SURVIVAL RATE; SWEDEN; YOUNG ADULT;

EID: 84889963088     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-586     Document Type: Article

References (29)

1. Brisson M, Edmunds WJ. Epidemiology of varicella zoster virus in England and Wales. J Med Virol 2003, 70(Suppl 11):S9-S14.
2. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010, 48(Suppl 1):S2-S7.
3. Oxman MN. Clinical manifestations of herpes zoster. Varicella-zoster Virus: Virology and Clinical Management 2000, 246-275. Cambridge, UK: Cambridge University Press, Arvin AM, Gershon AA.
4. Gonzalez Chiappe SG, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al. Herpes zoster: Burden of disease in France. Vaccine 2010, 28(50):7933-7938. 10.1016/j.vaccine.2010.09.074, 20946861.
5. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4(1):26-33. 10.1016/S1473-3099(03)00857-0, 14720565.
6. Gnann JW, Whitley RJ. Clinical practise. Herpes zoster. New Engl J Med 2002, 347(5):340-346. 10.1056/NEJMcp013211, 12151472.
7. Li Q, Chen N, Yang J, Zhou M, Zhang Q, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009, 15(2):CD006866. Review.
8. Oxman MN, Levin LJ, Johnson GR, Schmader KE, Straus SE, Gelb LD. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New Engl J Med 2005, 352(22):2271-2284. 10.1056/NEJMoa051016, 15930418.
9. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012, 55(10):1320-1328. 10.1093/cid/cis638, 22828595.
10. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008, 122(3):e744-e751. 10.1542/peds.2008-0567, 18762511.
11. Höhle M, Siedler A, Bader HM, Ludwig M, Heininger U, Von Kries R. Assessment of varicella vaccine effectiveness in Germany: a time-series approach. Epidemiol Infect 2011, 139(11):1710-1719. 10.1017/S0950268810002815, 21156098.
12. Svahn A, Berggren J, Parke A, Storsaeter J, Thorstensson R, Linde A. Changes in seroprevalence to four herpesviruses over 30 years in Swedish children aged 9-12 years. J Clin Virol 2006, 37(2):118-123. 10.1016/j.jcv.2006.07.012, 16971177.
13. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology 2007, 120(4):435-446. 10.1111/j.1365-2567.2007.02555.x, 2265901, 17313487.
14. Astrand B, Hovstadius B, Antonov K, Petersson G. The Swedish National Pharmacy Register. Stud Health Technol Inform 2007, 129(Pt 1):345-349.
15. Albert J, Andersson J, Aurelius E, Beermann B, Berglund J, Bergström T, , et al. and the Swedish consensus group Pharmacotherapy in Herpes Simplex Varicella- and Herpes Zoster infections. Inf Swed Med Prod Agency 2005, 4:345-349. and the Swedish consensus group.
16. Volpi A, Gross G, Hercegova J, Johnson RW. Current management of herpes zoster: the Eureopean view. Am J Clin Dermatol 2005, 6(5):317-325. 10.2165/00128071-200506050-00005, 16252931.
17. Statistics from the National Board of Health and Welfare. http://www.socialstyrelsen.se/statistics (last accessed in Dec 2012).
18. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009, 24(11):659-67. 10.1007/s10654-009-9350-y, 2773709, 19504049.
19. The National Patient Register in english. http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish (last accessed in Dec 2012).
20. The Swedish National cause of death register. http://www.socialstyrelsen.se/register/dodsorsaksregistret (last accessed in Dec 2012).
21. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009, 27(4):520-9. 10.1016/j.vaccine.2008.11.012, 19027048.
22. Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013, 13:170. doi:10.1186/1471-2334-13-170, 10.1186/1471-2334-13-170, 3637114, 23574765.
23. Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Seroprevalence of varicella-zoster in Korea. J Med Virol 2010, 82(12):2123-6. 10.1002/jmv.21917, 20981803.
24. Persson A, Bergström T, Lindh M, Namvar L, Studahl M. Varicella -zoster virus CNS disease-viral load, clinical manifestations and sequels. J Clin Virol 2009, 46(3):249-53. 10.1016/j.jcv.2009.07.014, 19709927.
25. Ross CA, Brown WK, Clarke A, Caldwell WF, Gordon ER, Harvey J, et al. Herpes zoster in general practice. J R Coll Gen Pract 1975, 25(150):29-32. 2157665, 1177201.
26. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leple'ge A, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001, 33(1):62-9. 10.1086/320884, 11389496.
27. Chapman RS, Cross KR, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003, 21(19-20):2541-7.
28. Fleming DM, Cross KW, Cobb WA, Chapman RS. Gender difference in the incidence of shingles. Epidemiol Infect 2004, 132(1):1-5. 10.1017/S0950268803001523, 2870070, 14979582.
29. Loikas D, Wettermark B, von Euler M, Bergman U, Schenck-Gustafsson K. Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden. BMJ Open 2013, 3(5):e002378. doi:10.1136/bmjopen-2012-002378, 3646185, 23645921.